« Back
Home /
Capecitabine

Capecitabine

Item no.	HY-B0016-5g
Manufacturer	MedChem Express
CASRN	154361-50-9
Amount	5 g
Quantity options	10 mM/1 mL 1 g 500 mg 5 g
Category	Metabolism Cholesterol & Lipid Metabolism Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]PharmD CM, et al. Capecitabine: A review. Clinical Therapeutics. 2005 Jan; 27(1): 23-44.\|[2]Guichard SM, et al. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. Eur J Cancer. 2008 Jan;44(2):310-7.
Smiles	O[C@H]1[C@@H](O)[C@H](N2C=C(C(NC(OCCCCC)=O)=NC2=O)F)O[C@@H]1C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	154361-50-9
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Apoptosis; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	359.35
Product Description	Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 250 mg/mL (ultrasonic)\|H2O: 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-B0016-5g-safety-datasheet.pdf